Krug K*,Jaehnig EJ*,Satpathy S* et.al. Proteogenomics redefines breast cancer biological subtype classifications and nominates therapeutic targets. Cell. 2020 Nov 25;183(5):1436-1456.e31. *co-first authorship
Gillette MA*, Satpathy S*, Cao S, et al. Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma. Cell. 2020 Jul 9;182(1):200-225.e35. *Equal contribution
Satpathy S, Jaehnig EJ, Krug K, et al. Microscaled proteogenomic methods for precision oncology. Nat Comm. 2020 Jan 27;11(1):532.
Udeshi ND, Mani DC, Satpathy S et al. Rapid and deep-scale ubiquitylation profiling for biology and translational research. Nat Comm. 2020 Jan 17;11(1):359.
Weiner BT, Narita T, Satpathy S, et al. Time-resolved analysis reveals rapid dynamics and broad scope of the CBP/p300 acetylome. Cell. 2018 Jun 28;174(1):231-244.e12. D
Satpathy S, Wagner SA, Beli P, et al. Systems-wide analysis of BCR signalosomes and downstream phosphorylation and ubiquitylation. Mol Syst Biol. 2015 Jun 2;11(6):810.
Shankha Satpathy, Ph.D.
Shankha Satpathy is a senior research scientist working in the Proteomics Platform at the Broad Institute of MIT and Harvard under the direction of Steven A. Carr. As part of the CPTAC consortium, Satpathy leads several clinical proteomics and proteogenomic projects. Of note was the development of a proteogenomics workflow for core-needle biopsy and its application in clinical trials, and the first comprehensive proteogenomic characterization of lung adenocarcinoma that Satpathy co-led with research groups within the CPTAC consortium. As part of the proteomics platform, he is also involved in several proteomics technology development areas, and also contributes to several academic- and industry-partnered collaborative projects using mass spectrometry and other proteomic tools to investigate interesting biological questions with potential translational impact. His work intersects multiple disciplines and involves both basic scientists and clinicians.
Satpathy joined the Broad Institute in September 2017 as a postdoctoral associate, moving into a research scientist post in 2019 and his current post in October 2020. He conducted his doctoral research in the application of proteomics to decipher immune signaling pathways, at Novo Nordisk Foundation Center for Protein Research in Copenhagen and earned his Ph.D. from the University of Copenhagen in 2017. He also holds a M.S. in biochemistry and molecular biology from the University of Calgary and a B.Tech. in biotechnology from Vellore Institute of Technology, India.
Contact Shankha Satpathy via email at firstname.lastname@example.org.